Completed PHASE3 INTERVENTIONAL 3-arm NCT00517036

Omega-3 Fatty Acids for Treating Adults With Major Depression

Omega-3 Fatty Acids for Treatment of Major Depression: Differential Effects of EPA and DHA, and Associated Biochemical and Immune Parameters

Sponsor: Cedars-Sinai Medical Center

Conditions Depression

Interventions DHA omega-3 fatty acid EPA omega-3 fatty acid Placebo comparator

Updated 5 times since 2017 Last updated: Apr 2, 2013 Started: Jul 31, 2006 Primary completion: Jan 31, 2011 Completion: Jan 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Depression, this trial is completed. The trial is conducted by Cedars-Sinai Medical Center and has accumulated 5 data snapshots since 2006. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cedars-Sinai Medical Center
Massachusetts General Hospital
National Institute of Mental Health (NIMH)

Data source: Cedars-Sinai Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Los Angeles, United States